Keros Therapeutics, Inc. (KROS)
20.26
+0.13
(+0.65%)
USD |
NASDAQ |
Dec 19, 16:00
20.21
-0.05
(-0.25%)
After-Hours: 20:00
Keros Therapeutics EPS Diluted (Quarterly): -0.1792 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 6.211 |
| Pfizer Inc. | 0.6197 |
| Innoviva, Inc. | 1.082 |
| Ocugen, Inc. | -0.066 |
| Bionano Genomics, Inc. | -1.593 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.28M |
| Revenue (Quarterly) | 14.26M |
| Total Expenses (Quarterly) | 21.54M |
| Enterprise Value | -58.80M |
| Gross Profit Margin (Quarterly) | 97.23% |
| Profit Margin (Quarterly) | -51.04% |
| Earnings Yield | 7.62% |
| Operating Earnings Yield | 5.29% |
| Normalized Earnings Yield | 7.616 |